Alejandro Patino - Genomma Lab President
| LABB Stock | MXN 25.78 0.27 1.06% |
President
Mr. Alejandro Baston Patino serves as VicePresident of International and Sales Development of Genomma Lab Internacional, S.A.B. de C.V. since 2015. He joined in the Company as Vice President of Commercial Strategy in 2008. Between 2007 and 2008, he has served as Chief Executive Officer of Depilite, and from 1999 to 2007, he acted as Director of Sales of OCESA. In the past, he worked at Hotel InterContinental, Hotel Stouffer Presidente, Hotel Las Brisas, Hoteles Camino Real and Hoteles Westin. He holds a diploma in Advanced Management and Sales from Insitituto Tecnologico y de Estudios Superiores de Monterrey and has attended to courses in Marketing and Business at the Cornell University and University of California, Berkeley. since 2015.
| Age | 51 |
| Tenure | 9 years |
| Phone | 52 55 5081 0000 |
| Web | https://www.genommalab.com |
Genomma Lab Management Efficiency
The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Alvaro Garza | Alfa SAB de | 55 | |
| Paulino Mendivil | Alfa SAB de | 68 | |
| Alfredo Perez | Grupo Mxico SAB | 70 | |
| Carlos Barrera | Alfa SAB de | 68 | |
| Daniel Quintanilla | Grupo Mxico SAB | 43 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 |
Genomma Lab Internacional Leadership Team
Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Emerson, Independent Director | ||
| Cesar Lopez, Vice President of Global Marketing | ||
| Efran Crdova, Deputy Sec | ||
| Carlos Alonso, Independent Director | ||
| Marianne Velasco, Global HR | ||
| Jorge Munoz, Independent Director | ||
| Ignacio Rodriguez, Independent Director | ||
| Alejandro Patino, Executive Vice President of Human Capital and Commercial Expansion | ||
| L Porres, Legal Officer | ||
| Rodrigo Aspra, Chairman of the Board, Independent Director | ||
| Juan Gavito, Independent Director | ||
| Antonio Galland, Executive Vice President, Chief Financial and Chief Administrative Officer | ||
| Hector Gonzalez, Independent Director | ||
| Burkhard Wittek, Director | ||
| Alejandro Patio, Media, Relations | ||
| Javier Castilla, Independent Director | ||
| Engineer Galland, Exec CFO | ||
| Sabrina Aspra, Director of International Operations, Director | ||
| Mximo Juda, Advisor | ||
| Daniel Neria, Head Relations | ||
| Juan Alonso, Independent Director | ||
| Santiago Pelaez, Vice President of Industrial and Research and Development | ||
| Jorge Valderrama, Chief Executive Officer | ||
| Juan Sparvieri, Chief Operating Officer, Vice President | ||
| Leticia Herrera, Global Director of Human Resources (Genomma Experience) |
Genomma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 20.43 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 13.61 X | |||
| Price To Book | 1.51 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genomma Stock Analysis
When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.